ISDA

Deposition Date 2013-01-16

Release Date 2013-02-27

Last Version Date 2024-11-06

Entry Detail

PDB ID:

4ISI

Keywords:

HYDROLASE/Hydrolase Inhibitor

Title:

Structure of FACTOR VIIA in complex with the inhibitor (6S)-N-(4-CARBAMIMIDOYLBENZYL)-1-CHLORO-3-(CYCLOBUTYLAMINO)-8,8-DIETHYL-4-OXO-4,6,7,8-TETRAHYDROPYRROLO[1,2-A]PYRAZINE-6-CARBOXAMIDE

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Cricetinae

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.94 Å

R-Value Free:

0.22

R-Value Work:

0.20

R-Value Observed:

0.21

Space Group:

P 41 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Factor VII heavy chain
Gene (Uniprot):F7
Chain IDs:A (auth: H)
Chain Length:254
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P08709 Pfam ID:PF00089, PF14670 EC:3.4.21.21

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Factor VII light chain
Gene (Uniprot):F7
Chain IDs:B (auth: L)
Chain Length:55
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P08709 Pfam ID:PF00089, PF14670 EC:3.4.21.21

Ligand Molecules

1GG

Primary Citation

Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors.

Zhang, X, Glunz, P.W, Jiang, W, Schmitt, A, Newman, M, Barbera, F.A, Bozarth, J.M, Rendina, A.R, Wei, A, Wen, X, Rossi, K.A, Luettgen, J.M, Wong, P.C, Knabb, R.M, Wexler, R.R, Scott Priestley, E.Show

Bioorg.Med.Chem.Lett. 23 1604 1607 (2013)

PMID: 23416003 DOI: 10.1016/j.bmcl.2013.01.094

Abstact

Bicyclic pyrazinone and pyrimidinone amides were designed and synthesized as potent TF-FVIIa inhibitors. SAR demonstrated that the S2 and S3 pockets of FVIIa prefer to bind small, lipophilic groups. An X-ray crystal structure of optimized compound 9b bound in the active site of FVIIa showed that the bicyclic scaffold provides 5 hydrogen bonding interactions in addition to projecting groups for interactions within the S1, S2 and S3 pockets. Compound 9b showed excellent FVIIa potency, good selectivity against FIXa, Xa, XIa and chymotrypsin, and good clotting activity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures